LoginRegister

    Cipla secures marketing rights for cancer drug in US

    Written by Ruby Khatun Khatun   |  
    Cipla secures marketing rights for cancer drug in US

    New Delhi: Drug major Cipla said its subsidiary has secured rights from Hyderabad-based MSN Laboratories to market and distribute colon cancer treatment drug Capecitabine in the US market.


    Cipla USA, Inc, a subsidiary of the company will be marketing the drug in strengths of 150 and 500 mg tablets.


    The company's product is the generic equivalent of Genentech's Xeloda.


    Capecitabine tablets are indicated in patients with colon cancer and for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.


    As per IQVIA (IMS Health) data, Xeloda and its generic equivalents had sales of around USD 178 million in the US for the 12-month period ending June 2018.

    armcancer drugCapecitabineCapecitabine tabletsCiplacolon cancerdistributeGenentechgeneric equivalentmarketmarketing rightsmetastatic breast cancerMSN LaboratoriessecuresUSUS marketXeloda
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X